IRIDA syndrome
eye-REE-dah syndrome
Also known as: Iron-Refractory Iron Deficiency Anemia, IRIDA
At a Glance
What is IRIDA syndrome?
IRIDA syndrome is a rare genetic disorder that primarily affects the body's ability to absorb iron, leading to iron deficiency anemia. The condition mainly impacts the hematologic system, as iron is crucial for producing healthy red blood cells. It is caused by mutations in the TMPRSS6 gene, which plays a role in regulating iron homeostasis. Over time, individuals with IRIDA may experience persistent anemia despite iron supplementation. Early symptoms often include fatigue, pallor, and delayed growth in children, while later symptoms can involve more severe fatigue and developmental delays. Early diagnosis is critical to manage symptoms and prevent complications. The condition can place a significant emotional and financial burden on families due to ongoing medical care needs. Prognosis varies, but with proper management, individuals can lead relatively normal lives. Daily life for those affected may involve regular medical check-ups and iron supplementation. The disorder does not typically affect life expectancy, but quality of life can be impacted by chronic anemia. Support from healthcare providers and family is essential for managing the condition effectively.
Medical Definition
IRIDA syndrome is characterized by iron-refractory iron deficiency anemia due to mutations in the TMPRSS6 gene, affecting iron regulation. Pathologically, it involves impaired hepcidin regulation, leading to decreased iron absorption and utilization. Histologically, bone marrow examination may reveal erythroid hyperplasia with microcytic, hypochromic red blood cells. It is classified under genetic disorders with an autosomal recessive inheritance pattern. Epidemiologically, it is an extremely rare condition with a prevalence of approximately 1 in 1,000,000 individuals. The disease course involves chronic anemia that is unresponsive to oral iron therapy but may partially respond to intravenous iron administration.
IRIDA syndrome Symptoms
Symptoms vary in severity between individuals. Early diagnosis and management can significantly improve outcomes.
Very Common
Microcytic anemia manifests as fatigue, weakness, and pallor due to reduced hemoglobin levels. It is caused by a defect in iron metabolism, particularly involving the hormone hepcidin, leading to iron-restricted erythropoiesis. Over time, the anemia can worsen if not managed, but it may stabilize with appropriate treatment. This condition affects daily life by reducing physical stamina and cognitive function, but iron supplementation and erythropoiesis-stimulating agents can help manage symptoms.
Hypochromic anemia presents with pale red blood cells due to insufficient hemoglobin content. The underlying mechanism involves impaired iron utilization, often linked to mutations affecting iron transport proteins. If untreated, it can lead to chronic fatigue and developmental delays in children. Regular monitoring and iron therapy can mitigate these effects, improving quality of life.
Fatigue in IRIDA syndrome is characterized by persistent tiredness and lack of energy. It results from inadequate oxygen delivery to tissues due to low hemoglobin levels. The severity of fatigue can fluctuate, often worsening with physical exertion. Managing anemia through medical interventions can alleviate fatigue, allowing patients to engage more fully in daily activities.
Common
Pallor is noticeable as a pale complexion and is a direct consequence of reduced red blood cell count. It occurs due to decreased hemoglobin, which gives blood its red color. While pallor is often a chronic condition, it can improve with effective treatment of the underlying anemia. It can affect self-esteem and social interactions, but reassurance and cosmetic solutions can help.
Delayed growth in children with IRIDA syndrome is marked by slower physical development compared to peers. This is primarily due to chronic anemia, which affects nutrient and oxygen delivery to growing tissues. Without intervention, growth delays can become more pronounced, potentially leading to short stature. Nutritional support and anemia management can promote more typical growth patterns.
Developmental delays may manifest as slower achievement of milestones such as walking and talking. These delays are linked to reduced oxygen supply to the brain due to anemia. Over time, delays can impact educational performance and social skills. Early intervention with therapies and educational support can help mitigate these effects.
Less Common
Jaundice is characterized by yellowing of the skin and eyes, resulting from increased bilirubin levels. It can occur due to hemolysis or ineffective erythropoiesis, both associated with anemia. Jaundice may fluctuate in severity and is typically more noticeable during anemia exacerbations. Treatment of the underlying anemia can reduce jaundice, improving appearance and comfort.
Splenomegaly, or enlarged spleen, can occur as the organ works harder to filter abnormal red blood cells. This is a compensatory response to anemia and can lead to discomfort or pain in the left upper abdomen. Over time, splenomegaly can increase the risk of spleen rupture or infection. Regular monitoring and addressing the anemia can help manage spleen size and associated risks.
What Causes IRIDA syndrome?
IRIDA syndrome is caused by mutations in the TMPRSS6 gene, located on chromosome 22q12.3. The TMPRSS6 gene encodes the matriptase-2 protein, a type II transmembrane serine protease. Matriptase-2 normally regulates the expression of hepcidin, a key hormone in iron homeostasis, by cleaving membrane-bound hemojuvelin. Mutations in TMPRSS6 disrupt the protease activity of matriptase-2, leading to inappropriate upregulation of hepcidin. Elevated hepcidin levels cause reduced iron absorption in the intestine and sequestration of iron in macrophages. This results in iron-restricted erythropoiesis and microcytic anemia. The lack of available iron affects mitochondrial function and energy production in erythroid precursors. Neighboring tissues, particularly those reliant on high iron turnover, experience functional deficits. The immune response may be altered due to changes in iron availability, potentially affecting neuroinflammation. White matter degeneration is not a primary feature of IRIDA syndrome, but systemic effects can influence overall health. Symptoms such as fatigue and pallor appear due to anemia and reduced oxygen delivery to tissues. The specific pattern of symptoms is related to the role of iron in erythropoiesis and cellular metabolism. Disease severity varies between patients due to differences in mutation type, residual protein function, and environmental factors such as diet.
How is IRIDA syndrome Diagnosed?
Typical age of diagnosis: IRIDA syndrome is typically diagnosed in early childhood, often before the age of 2, when children present with unexplained microcytic anemia that is unresponsive to oral iron supplementation. Diagnosis may occur later if the condition is mild or if there is a delay in recognizing the pattern of iron-refractory anemia.
Clinicians look for signs of anemia such as pallor, fatigue, and developmental delay. A detailed family history is important to identify any hereditary patterns of anemia. Physical examination may reveal pallor and sometimes hepatosplenomegaly. This step helps to differentiate IRIDA from other causes of anemia and directs further testing.
Ultrasound of the abdomen may be used to assess for hepatosplenomegaly. Imaging typically does not show specific abnormalities directly related to IRIDA but can help rule out other causes of anemia such as tumors or structural abnormalities. Findings that exclude other conditions support the diagnosis of IRIDA. Imaging is primarily used to ensure no other underlying conditions are contributing to the anemia.
Complete blood count and serum iron studies are ordered, showing microcytic anemia with low serum iron and transferrin saturation but normal or high ferritin levels. The absence of response to oral iron supplementation is a key biomarker. Abnormal results guide the clinician to consider genetic testing for IRIDA. These results help distinguish IRIDA from iron deficiency anemia and other anemias.
Genetic testing focuses on sequencing the TMPRSS6 gene, which is responsible for IRIDA. Mutations such as missense or nonsense mutations in this gene confirm the diagnosis. Results provide a definitive diagnosis and are crucial for family counseling regarding the hereditary nature of the condition. Genetic testing informs the risk assessment for other family members and potential future offspring.
IRIDA syndrome Treatment Options
Intravenous iron therapy is the mainstay treatment, as oral iron is ineffective. The mechanism involves bypassing the dysfunctional iron absorption pathway. Specific drugs used include iron sucrose and ferric carboxymaltose. Clinical evidence shows improvement in hemoglobin levels and overall anemia symptoms. Limitations include potential allergic reactions and the need for repeated infusions.
Nutritional counseling focuses on optimizing dietary intake to support overall health. The goal is to ensure adequate nutrition and support growth and development. Sessions may occur monthly and last about an hour. Measurable outcomes include improved growth parameters and energy levels. Long-term benefits include better management of symptoms and enhanced quality of life.
Splenectomy is rarely indicated but may be considered in cases of severe hypersplenism. The procedure involves the surgical removal of the spleen. Expected benefits include reduced hemolysis and improved anemia. Surgical risks include infection and thrombosis. Post-operative care requires vaccinations and monitoring for potential complications.
The care team typically includes a hematologist, nutritionist, and social worker. Interventions focus on managing anemia symptoms and providing psychosocial support. Strategies include counseling and educational sessions for families. Family education is crucial for understanding the condition and managing expectations. Long-term monitoring involves regular follow-ups to adjust treatment plans as needed.
When to See a Doctor for IRIDA syndrome
- Severe fatigue — this could indicate a critical drop in hemoglobin levels requiring immediate medical intervention.
- Unexplained bruising or bleeding — may suggest severe anemia or coagulopathy needing urgent evaluation.
- Shortness of breath — could signify severe anemia affecting oxygen delivery, necessitating emergency care.
- Persistent pallor — may indicate ongoing anemia; consult a doctor for further investigation.
- Delayed growth in children — could suggest chronic anemia impacting development; seek pediatric evaluation.
- Frequent infections — may be a sign of immune compromise due to anemia; discuss with a healthcare provider.
- Mild fatigue — monitor energy levels and maintain a balanced diet; consult a doctor if it worsens.
- Occasional dizziness — track occurrences and ensure adequate hydration; seek advice if persistent.
IRIDA syndrome — Frequently Asked Questions
Is this condition hereditary?
IRIDA syndrome is inherited in an autosomal recessive pattern, meaning both copies of the gene in each cell have mutations. Parents of an individual with IRIDA syndrome are carriers, typically not showing symptoms. The probability of passing the condition to children is 25% if both parents are carriers. De novo mutations are not commonly associated with this condition. Genetic counseling is recommended for affected families to understand inheritance risks and carrier status.
What is the life expectancy for someone with this condition?
Life expectancy in IRIDA syndrome can vary based on the severity and management of the condition. Early diagnosis and appropriate treatment can significantly improve outcomes. Mortality is rarely directly caused by the condition itself but may result from complications such as severe anemia. Treatment with iron supplementation and addressing underlying causes can enhance survival. Realistic expectations include a normal lifespan with proper management and monitoring.
How is this condition diagnosed and how long does diagnosis take?
Diagnosis of IRIDA syndrome involves a combination of clinical evaluation, blood tests, and genetic testing. The time from first symptoms to diagnosis can vary, often taking months to years due to its rarity and nonspecific symptoms. Hematologists and geneticists are typically consulted during the diagnostic process. Delayed diagnosis is common due to overlapping symptoms with other forms of anemia. Genetic testing confirming mutations in the TMPRSS6 gene finally confirms the diagnosis.
Are there any new treatments or clinical trials available?
Current research in IRIDA syndrome focuses on gene therapy and novel iron supplementation strategies. Promising approaches include targeting the underlying genetic mutations to restore normal iron metabolism. ClinicalTrials.gov is a resource for finding ongoing trials; patients should discuss trial participation with their doctors. Key questions for doctors include potential benefits and risks of new treatments. While some treatments are in early stages, advancements may be available in the next few years.
How does this condition affect daily life and activities?
IRIDA syndrome can impact mobility and self-care due to chronic fatigue and anemia. Educational performance may be affected by cognitive fatigue and concentration difficulties. Social and emotional challenges include coping with chronic illness and potential stigma. Family burden involves managing medical appointments and treatment regimens. Supports such as educational accommodations and counseling can significantly improve quality of life.
Support & Resources
References
Content generated with support from peer-reviewed literature via PubMed.
- 1.Case Report: Clinical and Hematological Characteristics of εγδβ Thalassemia in an Italian Patient.
Fotzi I, Pegoraro F, Chiocca E et al. · Front Pediatr · 2022 · PMID: 35372167
This content is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.Last reviewed: 2026-05-01